DGITH Group

Oncolytic virotherapy represents one of the most innovative directions in modern oncology, offering a treatment approach that is fundamentally different from chemotherapy, radiation, or surgery. Instead of relying on drugs that target rapidly dividing cells or invasive techniques to remove tumors, oncolytic virotherapy uses specially modified viruses to infect and destroy cancer cells. These viruses are engineered to replicate only inside malignant cells, causing them to burst while leaving healthy tissues largely unharmed. This selective ability makes oncolytic viruses a powerful tool in the search for safer, more precise cancer interventions.

Another significant benefit of this treatment lies in the immune response it triggers. When cancer cells are destroyed by viral replication, they release antigens that alert the immune system to the presence of disease. This process helps the body recognize cancer more effectively, sometimes enhancing the results achieved by immunotherapies. In this way, oncolytic virotherapy does not act only as a direct cell-killing mechanism but also as a strong immune system activator. Clinical applications are expanding rapidly, with research exploring its use against melanoma, brain tumors, liver cancer, and other hard-to-treat malignancies. As developments continue, this therapy promises to transform oncology by offering personalized, immune-stimulating, and targeted treatment options.

FAQ

1. What is oncolytic virotherapy?

It is a cancer treatment that uses modified viruses to attack and destroy cancer cells.

2. Can healthy cells be infected?

Engineered viruses are designed to avoid harming healthy tissue.

3. Does it strengthen the immune system?

Yes, it helps the immune system recognize and fight cancer more effectively.

4. Is oncolytic virotherapy used alone?

It can be used alone or combined with immunotherapy or chemotherapy.

5. Is this therapy available worldwide?

Availability varies by country and depends on approvals and ongoing clinical trials.